Following recent trial success in using CRISPR-Cas9 for the treatment of diseases such as sickle cell anemia and beta thalassemia, researchers are excited for a new era of transformative medicine.
Following recent trial success in using CRISPR-Cas9 for the treatment of diseases such as sickle cell anemia and beta thalassemia, researchers are excited for a new era of transformative medicine. Given the success in trials so far, it’s possible that CRISPR-based medicine could be approved as soon as 2023.